IL326550A - Methods of treating blood disorders with vwf-targeted monospecific antibodies - Google Patents

Methods of treating blood disorders with vwf-targeted monospecific antibodies

Info

Publication number
IL326550A
IL326550A IL326550A IL32655026A IL326550A IL 326550 A IL326550 A IL 326550A IL 326550 A IL326550 A IL 326550A IL 32655026 A IL32655026 A IL 32655026A IL 326550 A IL326550 A IL 326550A
Authority
IL
Israel
Prior art keywords
vwf
targeted
methods
blood disorders
treating blood
Prior art date
Application number
IL326550A
Other languages
Hebrew (he)
Original Assignee
Hemab Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemab Aps filed Critical Hemab Aps
Publication of IL326550A publication Critical patent/IL326550A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL326550A 2023-08-16 2024-08-16 Methods of treating blood disorders with vwf-targeted monospecific antibodies IL326550A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363519955P 2023-08-16 2023-08-16
PCT/EP2024/073157 WO2025037032A1 (en) 2023-08-16 2024-08-16 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (1)

Publication Number Publication Date
IL326550A true IL326550A (en) 2026-04-01

Family

ID=92675879

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326550A IL326550A (en) 2023-08-16 2024-08-16 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Country Status (6)

Country Link
AR (1) AR133583A1 (en)
AU (1) AU2024324856A1 (en)
CO (1) CO2026002476A2 (en)
IL (1) IL326550A (en)
TW (1) TW202509085A (en)
WO (1) WO2025037032A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides
CN119032109A (en) * 2022-02-15 2024-11-26 赫迈博私人有限责任公司 Methods for treating blood disorders using monospecific antibodies targeting VWF

Also Published As

Publication number Publication date
TW202509085A (en) 2025-03-01
WO2025037032A1 (en) 2025-02-20
CO2026002476A2 (en) 2026-03-16
AU2024324856A1 (en) 2026-02-26
AR133583A1 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
CA3244108A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
IL316615A (en) Bispecific antibodies and methods of treating ocular disease
AR098663A1 (en) MULTIFUNCTIONAL ANTIBODIES THAT JOIN EGFR AND MET
IL285308A (en) Methods for the treatment of eye cancer using anti-met antibodies and bispecific antigen-binding molecules that bind met
IL299339A (en) Antibodies and methods for treating claudin-associated diseases
IL314322A (en) Methods for treating patients with an autoantibody-mediated disease
EP4139364A4 (en) BISPECIFIC ANTIBODIES FOR THE TREATMENT OF CD47-ASSOCIATED DISEASES
IL287832A (en) Methods for administering anti-cd38 antibody for the treatment of multiple myeloma
EA202192907A1 (en) MONOCLONAL ANTIBODY THAT SPECIFICLY BINDS TO GITR
IL286337A (en) Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
PH12022550647A1 (en) Anti-stem cell factor antibodies and methods of use thereof
IL289842A (en) Humanized anti-liv1 antibodies for the treatment of cancer
EP4069747A4 (en) COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-HER2 ANTIBODIES FOR TUMOR TREATMENT
IL317946A (en) Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and fcrh5xcd3 bispecific antibodies for the treatment of blood cancers
AR116668A1 (en) AGONIST ANTIBODIES AGAINST CD200R AND ITS USES
EA201990613A1 (en) ANTIBODIES AGAINST GREEMLIN-1 (GREM1) AND METHODS OF THEIR APPLICATION FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
IL291449A (en) Methods of treating epileptic patients with fenfluramine
IL290892A (en) Methods of treating vascular diseases
IL326550A (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
CA3301362A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
IL307556A (en) Methods of treating cancer with anti-tigit antibodies
IL318036A (en) Anti-pcrv and psl bispecific antibodies for treatment of bronchiectasis